Pradigastat sodium
Based on 2 publication(s) in Google Scholar
Pradigastat sodium (LCQ 908 sodium) is a selective and orally effective diacylglyceryl acyltransferase 1 (DGAT1) inhibitor with IC50 at 0.157 µM. Pradigastat is primarily used to study diseases associated with abnormal triglyceride metabolism. Pradigastat has anti-obesity and anti-diabetic effects. Pradigastat inhibited BCRP, OATP1B1, OATP1B3 and OAT3 activities with IC50 of 5 µM, 1.66µM, 3.34µM and 0.973µM, respectively. In addition, Pradigastat has antiviral activity and can inhibit hepatitis C virus replication in vitro.
For research use only. We do not sell to patients.
- CAS No.: 956136-98-4
- Formula: C25H23F3N3NaO2
- Molecular Weight:477.45
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Pradigastat sodium
More
Biological Activity
Diacylglycerol acyltransferase 1 (DGAT1)[1]
IC50: 5 µM (BCRP); IC50: 1.66 µM (OATP1B1); IC50: 3.34 µM (OATP1B3); IC50: 0.973 µM (OAT3)[2]
Pradigastat (0-50 μM; 1 h) inhibits BCRP-mediated efflux activity in a dose-dependent manner in overexpressing human ovarian cancer cell lines with an IC50 of 5 µM[2].
Pradigastat (0-50 μM; 5 minutes) inhibits OATP1B1, OATP1B3, and OAT3 activities in a concentration-dependent manner with IC50 of 1.66µM, 3.34µM and 0.973µM, respectively[2].
Pradigastat (2-20 μM; 8 h) inhibits the replication and production of hepatitis C virus in vitro[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 956136-98-4
-
Molecular Weight 477.45
-
Formula C25H23F3N3NaO2
-
SMILES
O=C(O[Na])C[C@H]1CC[C@H](C2=CC=C(C3=NC=C(NC4=CC=C(C(F)(F)F)N=C4)C=C3)C=C2)CC1
-
Synonyms
LCQ 908 sodium
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Neuron
2020 Jan 22;105(2):276-292.e5. PMID: 31786011 -
Curr Atheroscler Rep
Managing of Dyslipidaemia Characterized by Accumulation of Triglyceride-Rich Lipoproteins. [Abstract]2022 Jan;24(1):1-12. PMID: 35107764
Purity & Documentation
References
[1]. Meyers CD, et al. Effect of the DGAT1 inhibitor pradigastat on triglyceride and apoB48 levels in patients with familial chylomicronemia syndrome. Lipids Health Dis. 2015 Feb 18;14:8. [Content Brief]
[2]. Kulmatycki K, et al. Evaluation of a potential transporter-mediated drug interaction between ZD 4522 and pradigastat, a novel DGAT-1 inhibitor. Int J Clin Pharmacol Ther. 2015 May;53(5):345-55. [Content Brief]
[3]. Gane E, et al. A Diacylglycerol Transferase 1 Inhibitor Is a Potent Hepatitis C Antiviral in Vitro but Not in Patients in a Randomized Clinical Trial. ACS Infect Dis. 2017 Feb 10;3(2):144-151. [Content Brief]
[4]. Hong DJ, et al. Synthesis and biological evaluation of novel thienopyrimidine derivatives as diacylglycerol acyltransferase 1 (DGAT-1) inhibitors. J Enzyme Inhib Med Chem. 2020 Dec;35(1):227-234. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz